CapsoVision (NASDAQ:CV) executives used a fireside chat hosted by Roth Senior Research Analyst Kyle Bauser to outline the company’s origins, its capsule endoscopy platform for small bowel visualization, and development plans for future GI indications including colon and pancreas. Management also discussed its commercial footprint, the expected role of artificial intelligence in streamlining physician workflow, and recent financing and cash levels.
Company origins and long-term vision
Co-founder, President, and CEO Johnny Wang said CapsoVision grew out of his background in semiconductors and integrated circuit (IC) design. He described an early focus on innovating in capsule endoscopy by developing components and subsystems including image and video processing ICs, a CMOS image sensor, panorama optics, onboard storage, lighting, a magnetic power system, and accompanying software—designed to fit into a capsule form factor intended to operate for 15 hours on two watch batteries.
Looking forward, Wang said the company’s IPO thesis was based on accelerating growth in small bowel capsule endoscopy powered by AI and “exponential” growth trajectories for colon and pancreas cancer detection. He described a longer-term goal of “panenteric imaging” in a single non-invasive procedure with AI assistance, aimed at enabling detection and screening of multiple cancers throughout the gut.
CapsoCam Plus and the small bowel market
Senior Vice President of Global Sales Doug Atkinson described CapsoCam Plus as a capsule about the size of a fish oil supplement, built with four cameras oriented to capture a 360-degree view of the GI tract mucosal lining. He said the capsule uses onboard storage, eliminating the need for external equipment such as sensor arrays, belts, or data recorders used by some competitors. After retrieval, the capsule can be sent to CapsoVision’s download center in San José, and Atkinson emphasized what he described as a “single patient visit” workflow, including use in telehealth settings.
Atkinson said capsule endoscopy is commonly used to evaluate patients with blood in the stool and other symptoms such as abdominal pain and diarrhea, as well as in Crohn’s disease, cancer evaluation, and celiac disease. He estimated that roughly 55% to 60% of use is related to obscure GI bleeding.
On market sizing, Atkinson said the upper GI market—including esophageal, gastric, pancreatic, and small bowel—was projected to be $300 million by 2030. He characterized the colon market as $17.8 billion and noted that about 20 million Americans undergo colonoscopy each year. He added that the company’s goal is to pursue the contraindicated market and build a registry that it believes could support access to the screening market.
Differentiation and AI-assisted reading
Atkinson highlighted the capsule’s four laterally positioned cameras as a way to help address capsule “tumbling” and uncontrolled movement through the GI tract, arguing that the approach better mimics the view control of an optical colonoscope. He also said the lack of external equipment supports use in patients who may be contraindicated for competitor systems, including patients with implantable devices and certain high-BMI patients where signal transmission can be an issue.
Wang discussed an AI-assisted reading module the company submitted to the FDA in December. He said the AI is intended to save physician reading time—citing 20 to 30 minutes for small bowel reading—and argued that time savings could carry economic benefits for clinicians paid based on procedure volume. Wang also cited “awareness fatigue” during review and said reading sensitivity can drop over time, adding that second readings may be significantly lower. He said AI can help reduce observer fatigue and improve accuracy while increasing efficiency. The discussion did not include a specific expected FDA decision date.
Commercial footprint and pipeline timelines
Atkinson said the company has 26 direct sales representatives in the U.S. and plans to add territories where it makes geographic sense. He said the company sells direct in the U.S. and Germany and uses a mix of direct and distributor models across 69 countries. Atkinson also said that if the colon capsule is approved, CapsoVision expects to sell it using the existing sales force rather than building a separate team.
On product development timelines, Wang said the company’s plan is to submit its colon capsule in the third quarter of 2026. He said the pancreas study began in the first half of the year and noted participation from key opinion leaders, including leadership in pancreas-focused societies. Wang said the company intends to begin esophagus work after the colon submission. For early esophageal adenocarcinoma, he said work involving biopsy, pathology, and AI analysis would be done in 2027 and 2028, with stomach work in a similar timeframe. He also noted plans to enroll patients in regions such as Taiwan and Japan for stomach cancer given prevalence.
Canon partnership and financing update
Wang described the company’s partnership with Canon as focused on advanced sensor technology. He said Canon’s sensor capabilities could support higher frame rates, higher dynamic range, and higher resolution. He also referenced an additional $1 million tied to increased features in specifications and said the change was intended to implement CapsoVision patented technology that he believes provides an advantage.
Senior Vice President of Finance David Garcia said that as of December 31 the company had $10.1 million in cash and equivalents. He said CapsoVision also closed a $14 million private placement of equity, which he characterized as providing runway into 2026. Garcia said the company is investing in its colon study and other R&D projects, including work connected to Canon, and that management continues to evaluate financing options to keep the balance sheet “strong” as it moves through 2026.
About CapsoVision (NASDAQ:CV)
CapsoVision, Inc (NASDAQ: CV) is a medical device company specializing in advanced capsule endoscopy systems for gastrointestinal diagnostics. The company’s flagship product, the CapsoCam® Plus System, features a swallowable, tether-free capsule equipped with four side-viewing cameras that capture high-resolution, 360-degree images of the small intestine. By storing images internally rather than transmitting data wirelessly, CapsoCam Plus enables patients to maintain normal daily activities during the procedure and reduces the risk of signal loss or image drop-out.
In addition to its capsule hardware, CapsoVision offers CapsoCloud®, a secure, cloud-based platform that streamlines image retrieval, storage and reporting.
-logo-1200x675.png){kind=logo}
